What is Parallel Fluidics?
Parallel Fluidics operates at the intersection of advanced manufacturing and life sciences, providing the world's first on-demand microfluidic production service. By enabling scientific teams to transition from conceptual design to production-grade devices with unprecedented speed, the company effectively mitigates the technical risks that historically bottleneck innovation. Its platform serves critical verticals including drug discovery, precision medicine, and cell therapy, positioning Parallel Fluidics as an essential utility for organizations aiming to accelerate breakthroughs in patient care and sequencing technologies.
The company's market position is defined by its ability to compress the R&D cycle, offering a robust alternative to traditional, slow-moving prototyping methods. By standardizing the production of microfluidic components, Parallel Fluidics empowers researchers to focus on high-level scientific inquiry rather than the logistical hurdles of device fabrication.
How much funding has Parallel Fluidics raised?
Parallel Fluidics has raised a total of $8.8M across 2 funding rounds:
Unspecified
$1.8M
Angel/Seed
$7M
Unspecified (2021): $1.8M, investors not publicly disclosed
Angel/Seed (2024): $7M led by Praxis, 8VC, and J2 Ventures
Key Investors in Parallel Fluidics
8VC
8VC is a prominent technology investment firm that backs industry-transforming companies, leveraging a deep track record in smart enterprise platforms and Bio-IT.
J2 Ventures
J2 Ventures is an early-stage investment firm comprised of PhD scientists and physicians, focusing on pioneering technologies in biomedical engineering and advanced infrastructure.
Praxis
Praxis is a strategic investment partner focused on supporting high-growth ventures that demonstrate significant potential for long-term market disruption.
What's next for Parallel Fluidics?
With this major strategic investment, Parallel Fluidics is expected to aggressively expand its manufacturing capacity and deepen its integration within the global life sciences ecosystem. The capital will likely be deployed to enhance production throughput and broaden the company's service offerings to meet the increasing demand for precision-engineered diagnostic tools. As the firm moves into this next phase of growth, the focus will shift toward scaling operations to support larger enterprise clients, further cementing its role as a foundational partner in the next generation of biomedical engineering and sequencing advancements.
See full Parallel Fluidics company page
